GlassScriptPhysician profile
Timothy M Klepper
NPI 1164684965
$8,284.72
in general payments reported to CMS, 2019-2025
52 companies · $1,427 in 2025
The $1,427 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,114 · 2020: $1,028 · 2021: $1,013 · 2022: $993 · 2023: $1,291 · 2024: $1,417 · 2025: $1,427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,135.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,880.57 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $629.73 | 2019-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $592.26 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $492.05 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $473.57 | 2019-2025 | |
| Abbvie INC. | $472.20 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $403.00 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Glaxosmithkline, LLC. | $381.26 | 2019-2025 | Shingrix, Arexvy |
| Astellas Pharma US INC | $348.36 | 2019-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $298.37 | 2019-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $231.91 | 2019-2025 | Tradjenta, Jardiance |
| Exact Sciences Corporation | $171.30 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $164.77 | 2019-2023 | Trintellix |
| Dexcom, INC. | $148.34 | 2021-2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $133.73 | 2020-2024 | Rexulti |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Klepper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.